guest ::
| Home > Publications database > Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment. |
| Home > Publications database > Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment. |
| Journal Article (Review Article) | DKFZ-2023-00643 |
; ;
2023
Elsevier
Orlando, Fla. [u.a.]
Abstract: Fibroblast activation protein (FAP)-radioligand therapy might be effective in some patients without being curative. FAP-radioligands deliver ionizing radiation directly to FAP+ cancer-associated fibroblasts and, in some cancers, to FAP+ tumor cells; in addition, they indirectly irradiate FAP- cells in tumor tissue via cross-fire and bystander effects. Here, we discuss the potential to improve FAP-radioligand therapy through interfering with DNA damage repair, immunotherapy, and co-targeting cancer-associated fibroblasts. As the molecular and cellular effects of FAP-radioligands on the tumor and its microenvironment have not been investigated yet, we call for future research to close this gap in knowledge, which prevents the development of more effective FAP-radioligand therapies.
Keyword(s): Combination therapy ; Fibroblast activation protein ; Radioligand ; Theranostics ; Tumor microenvironment
; Clarivate Analytics Master Journal List ; Emerging Sources Citation Index ; IF < 5 ; JCR ; SCOPUS ; Web of Science Core Collection
|
The record appears in these collections: |
